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Abstract 
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in 
modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review 
(ICER). The principal objection to ICER reports has been that their modeled claims fail the standards of normal science: they are best 
seen as pseudoscience. The purpose of this latest commentary is to consider the recently released ICER report for Duchenne muscular 
dystrophy (DMD). As ICER has continued in the case of DMD to apply its modeled cost utility framework with consequent 
recommendations for pricing adjustments, these recommendations also lack credibility. This commentary emphasizes again not only 
why the ICER methodology fails to meet the standards of normal science but to point to the importance in rare diseases for accelerated 
approval, while recognizing that evidence generation will continue. While this assessment of the ICER DMD model does not imply any 
support for this methodology, a key point is the application of quality of life measures which fail to capture the experience of patients 
with DMD and, importantly, the interests of both patients and caregivers.   While ICER would argue that even with a limited evidence 
base it is important to address issues of pricing and access for new products, their reports are used as justification for coverage and 
reimbursement by insurers and health system decision makers without recognition of their lack of scientific merit. This rush to 
judgement by ICER must raise concerns about potentially adverse formulary decisions that result in access restrictions on new products. 
If ICER is to make a contribution to the entry of new products in the health market place then it should consider an alternative 
methodology that generates claims that are empirically evaluable in a timeframe relevant to health decision makers. As it stands, 
ICER’s recommendation should be rejected. This is not a research program that meets accepted scientific standards but one that relies 
on the willingness of an audience to accept the proposition that evidence is constructed not discovered.   
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Introduction 
On 15 August 2019 the Institute for Clinical and Economic 
Review (ICER), a not-for profit health technology assessment 
group, released its final report and meeting summary on 
Duchenne muscular dystrophy (DMD) 1. The report focused on 
an assessment of the comparative clinical effectiveness and 
value of two first-of-their-kind novel exon-skipping therapies, 
eteplirsen (Exondys) and golodirsen (under FDA review), 
together with the corticosteroid,  deflazacort (Emflaza). The 
base case comparator was prednisone, a mainstay of 
corticosteroid therapy for DMD. 
 
The ICER report concluded that, based on a comparative clinical 
assessment and then a modeled cost-per-QALY evaluation that 
‘there is no persuasive evidence that these exon-skipping 
therapies improve outcomes that matter to patients, including 
functional status, quality of life, or length of life. Eteplirsen has 
been on the market for three years and yet we still found 
notably inadequate data on patient outcomes. Corticosteroid 
therapy does improve outcomes in DMD, and  
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there is some evidence that deflazacort may have larger 
benefits and smaller harms than prednisone’.  
 
The purpose of this commentary, in common with previous 
commentaries on ICER reports published in INNOVATIONS in 
Pharmacy is to review the value claims for these products, in 
particular eteplirsen 2 3 4 5 6. The principal question is whether 
or not the techniques employed by ICER in making value claims 
meet the standards of normal science 7 8 9. If they do not then 
the value claims should be put to one side in favor of an 
alternative value assessment framework that generates value 
clams that are credible, evaluable and replicable.  
 
Duchenne Muscular Dystrophy  
DMD is classified as a rare disease. It is the most common and 
most severe of the nine types of muscular dystrophy. It is a 
genetic disorder caused by the absence of the protein 
dystrophin. It is characterized by progressive skeletal muscle 
degeneration and weakness that control movement. Onset is 
usually in early childhood, typically between the ages 3 and 5 
years. As it progresses, muscle weakness and atrophy impact 
the trunk and forearms and eventually other muscles. DMD 
results from mutations of the DMD gene on the short arm (p) 
of the X chromosome (Xp21.2). As this gene regulates 
production of the protein dystrophin that is associated with 
maintaining the integrity of the membrane of muscle cells, the 
absence of dystrophin is associated with this most severe form 
of muscular dystrophies (with a less severe form, Becker 
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muscular dystrophy associated with decreased dystrophin 
protein) 
 
DMD affects approximately 1 in 3,500 live male births with an 
estimated 20,000 children diagnosed with DMD each year. It is 
rapidly progressive with children exhibiting developmental 
delays, toe walking, a waddling gait, difficulty climbing stairs, 
rising from a sitting position, fractures and repeated falling. As 
the disease progresses other abnormalities may appear to 
include progressive spinal curvature, wasting of thigh and 
pectoral muscles and joint contractures. In the absence of 
interventions, leg braces may be needed by ages 8-9 and a 
wheelchair by ages 10 to 12.  
 
If a boy survives to late teens complications may appear such as 
cardiomyopathy, increased susceptibility to respiratory 
infections, coughing and respiratory failure.  Poor respiratory 
function can include headaches, difficulty concentrating and 
poor sleep patterns. Dysmotility of the gastrointestinal tract 
may also develop, with associated constipation and diarrhea. A 
recent descriptive study of the health profile of a cohort of DMD 
patients tracked from 1982 to 2012 from the Muscular 
Dystrophy Tracking and Research Network (MD STARnet) found 
that median years for critical milestones were: development of 
cardiomyopathy 16.7 years, initiation of non-invasive 
ventilation 18.0 years, gastronomy 19.0 years and death 21.8 
years 10. 
 
To add further to the burden of disease is the cognitive and 
neurobehavioral profile of DMD patients. A retrospective study 
of 59 boys found 27% had a full scale IQ of < 70,  44% with a 
learning disability  19% with intellectual disability, attention 
deficit hyperactivity disorder (ADHD) in 32%, autism spectrum 
disorders in 15% and anxiety in 27% 11. Further evidence of 
neuropsychological comorbidities from a self-report group 
(n=228) found 7.9% were considered to have epilepsy together 
with other brain-related comorbidities, to include ADHD, 
obsessive compulsive disorder, anxiety disorders and sleep 
disorders 12. Overall, approximately one third of DMD patients 
may have various elements of cognitive impairment.  
 
Chronic pain is also present in DMD patients, while often 
overlooked. A recent review of pain experience concluded that 
pain is pervasive in the DMD population, beginning in 
adolescence with an estimated two thirds reporting experience 
of pain13.   
 
At the same time, life expectancy has increased in DMD 
populations with the advent of corticosteroids and the 
application of better interventional techniques such as non-
invasive positive pressure ventilation. Current estimates are 
that on average life expectancy has increased from 19 to 26 
years, with some surviving into their 30s and 40s. At the same 
time, while the evidence from long-term data sets such as the 
TREAT-NMD Global Database indicate that while average life 
expectancy has increased there is associated greater disease 
variability in terms of progression14.  
 
Value Claims in DMD 
Understanding the complexity of DMD in its presentation and 
associated comorbidities is critical in any appraisal of its impact 
on patients, caregivers and the family group. If, for example, 
quality of life (QoL) or health related quality of life (HRQoL) are 
considered relevant outcomes in establishing the value case for 
interventions such as exon-skipping therapies, then care must 
be taken to ensure that measures for both patients and 
caregivers are appropriate. Value claims that rest on 
incomplete or inappropriate measures are not acceptable. At 
the same time, if value claims are expressed in QoL or HRQoL 
terms then these must be credible and evaluable.  
 
The same arguments apply to claims for intervention costs. If 
value proposition focus on comparative costs of, for example, a 
corticosteroid such as prednisone and the additional costs of an 
exon-skipping therapy, then these costs must be expressed in 
evaluable terms. Making claims for lifetime costs that are, by 
definition, non-evaluable hardly seems a useful endeavor.  
 
The requirement for testable hypotheses in the evaluation and 
provisional acceptance of claims made for products and devices 
is unexceptional. Since the 17th century, it has been accepted 
that if a research agenda is to advance, if there is to be an 
accretion of knowledge, there has to be a process of discovering 
new facts. Indeed, as early as the 16th century Leonardo da Vinci 
(1452 – 1519) in notes that appeared posthumously in 1540 for 
his Treatise on Painting (published in 1641) clearly anticipated 
the standards for the scientific method which were widely 
embraced a century later in rejecting thought experiments that 
fail the test of experience. By the 1660s, the scientific method, 
following the seminal contributions of Bacon, Galileo, Huygens 
and Boyle, had been clearly articulated by associations such as 
the Academia del Cimento in Florence (1657) and the Royal 
Society in England (founded 1660; Royal Charter 1662) with 
their respective mottos Provando e Riprovando (prove and 
again prove) and nullius in verba (take no man’s word for it) 15.  
By the early 20th century, standards for empirical assessment 
were put on a sound methodological basis by Popper in his 
advocacy of a process of ‘conjecture and refutation 16 17 .  
Hypotheses or claims must be capable of falsification; indeed, 
they should be framed in such a way that makes falsification 
likely. Life becomes more interesting if claims are falsified 
because this forces us to reconsider our models and the 
assumptions built into those models. This leads, then, to the 
obvious point that claims or models should not be judged on 
the realism or reasonableness of assumptions as representing 
an ‘acceptable’ imaginary perception of an unknown and 
unknowable future ‘reality’. We should not ‘take their word for 
it’; rather, we should reject it as pseudoscience. 
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Although Popper’s view on what demarcates science (e.g., 
natural selection) from pseudoscience (e.g., intelligent design) 
is now seen an oversimplification involving more than just the 
criteria of falsification, the demarcation problem remains18.  
Certainly, there are different ways of doing science but what all 
scientific inquiry has in common is the ‘construction of 
empirically verifiable theories and hypotheses’. Empirical 
testability is ‘one major characteristic distinguishing science 
from pseudoscience’; theories must be tested against data. 
Indeed paradoxically, while the development of pharmaceutical 
products and the evidence standards required by the Food and 
Drug Administration (FDA) for product evaluation and 
marketing approval are driven by adherence to the scientific 
method, once a product is launched and claims made for cost-
effectiveness and, in the case of ICER, pricing and access 
recommendations, the scientific method is put to one side.   
The rejection of a research program that meets the standards 
of normal science by groups such as ICER is best exemplified by 
the latest version of the Canadian health technology guidelines 
where it is stated: Economic evaluations are designed to inform 
decisions. As such, they are distinct from conventional research 
activities, which are designed to test hypotheses19. While this 
position puts modeled health technology assessment in the 
category of pseudoscience, it is also what may be described as 
a relativist position. Rather than subscribing to the position that 
the standards of normal science are the only standards to apply 
in health care decisions and value claims, the relativist believes 
that all perspectives are equally valid. Health care decisions are 
to be understood sociologically. No one body of evidence is 
superior to another. Results of a lifetime modeled simulation 
are on an equal basis with those of a pivotal Phase 3 
randomized clinical trial. For the relativist, the success of a 
scientific research program, in this case one built on 
hypothetical models and simulations, rests not on its ability to 
generate new knowledge but on its ability to mobilize the 
support of the community. Basing decisions on models and 
simulations underpins the consensus view that evidence is 
constructed, never discovered. Instead of coming to grips with 
reality science is about rhetoric, persuasion and authority. 
Truth is consensus. 
 
The ICER Reference Case 
Central to the ICER construction of value claims is the reference 
case. Standards for model building, the construction of 
imaginary worlds, are clearly stated with the preference for 
models that take a long-term or lifetime perspective with value 
propositions expressed in cost-per QALY terms. Once a cost-
per-QALY estimate (or estimates under different scenarios) has 
been constructed, the acceptability of a proposed product price 
is then assessed against cost-per-QALY willingness to pay 
thresholds (typically $50,000, $100,000 and $150,000 per QALY 
with exceptions for higher cut-offs for rare diseases). Whether 
a product ‘adds value’ is then determined in terms of its impact 
on estimated lifetime modeled QALYs set against a proposed 
lifetime product cost where both are driven by hypothetical 
constructed evidence. .   
 
Unfortunately, the position taken by the Canadian guidelines 
reflects the consensus view in health technology assessment. 
Over the past 30 years, literally thousands of modeled claims 
have been presented in the literature, including leading health 
technology assessment  journals. Annual reviews of the status 
of cost-effectiveness or modeled claims in the three journals, 
Pharmacoeconomics, Value in Health and the Journal of 
Medical Economics found that the majority of models 
presented non-evaluable claims (typically lifetime cost-per-
QALY) 20 21 22 23 24. Where models were funded by a 
manufacturer a high proportion supported, in their modeled 
cost-per-QALY assessment, the manufacturer’s product. While 
subscribing to modeling standards proposed by, for example, 
the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and the Academy of Managed Care 
Pharmacy (AMCP) all too many of the papers were essentially 
marketing exercises 25 26.  
 
At the same time with the emergence of the National Institute 
of Health and Care Excellence (NICE) in the UK in the late 1990s, 
the creation of imaginary worlds has received widespread 
support 27. Versions of the NICE reference case are found in the 
majority of single payer health systems. 
 
The point, of course, is that in advocating a reference case to 
support value propositions and the case for price discounts, it 
was never intended that the value claims expressed in cost-per-
QALY terms would be empirically evaluable. They were, as 
made clear by the CADTH guidelines, ‘for information only’. The 
only basis on which a reference case value claim could be 
challenged was by using the same reference standards to 
construct a different model. A model whose claims would 
similarly be non-evaluable. The debate would then center on 
the choice of assumptions with each side arguing that theirs is 
a more realistic yet imaginary construct.  
 
To be fair, however, if an agency such as NICE or the 
Pharmaceutical Benefits Advisory Committee in Australia 
(PBAC) require submissions for product reviews to subscribe to 
a reference case structure then, irrespective of concerns as to 
scientific status, manufacturers are obliged to create models 
that meet those standards 28. This does not mean that the US 
has to follow suit. The fact that ICER has taken upon itself a 
standards setting role is beside the point. There is no reason 
why formulary committees and health decision makers should 
accept the ICER reference case as relevant to health care 
decisions, particularly if it is seen as failing the standards of 
normal science. 
 
 The ICER Reference Case specifies the approach that ICER and 
its collaborators follow for cost-effectiveness analyses in 
constructing cost-per-QALY imaginary worlds29. This is little 
different from the initial reference case standards established 
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by NICE.  However, unlike agencies such as NICE and the PBAC, 
where the reference specifications are to inform manufacturers 
of the standards required for modeled submissions to the 
review agency, the ICER reference case is to establish the 
framework for the development of the ICER in-house model. 
Manufacturers are not asked to submit their own model, 
although this would be relatively easy if they have already 
developed models for other jurisdictions, but to merely have 
limited access to the ICER model as it is developed, with the 
opportunity to suggest modifications but without the possibility 
of major modifications or competing models. Although unlikely, 
it would be of interest to ask an academic center in the UK or 
Australia to undertake a review of ICER models with the results 
in the public domain. 
 
The options open for competing models within a reference case 
framework is readily seen in the response and transparency of 
NICE and its reviewers to manufacturer’s models. The 
manufacturer’s model may be accepted without change, 
accepted with modifications or rejected and an alternative 
model proposed. Critiques of the models proposed by 
manufacturers are not, of course, in terms of the empirical 
status of claims. This would be impossible given the reference 
case timeframes. 
 
The ICER DMD Model 
The objective of the ICER model was to ‘assess the cost-
effectiveness of deflazacort, eteplirsen and golodirsen for 
patients diagnosed with DMD in the US’. This translates to a 
model to judge the appropriateness of current pricing. In the 
case of deflazacort the comparison was between deflazacort 
and supportive care and prednisone and supportive care. 
Eteplirsen and golodirsen were assessed as add-on therapy to 
corticosteroids and supportive care and corticosteroids and 
supportive care alone. However, in the case of eteplirsen and 
golodirsen ’there was insufficient evidence to model specific 
treatment effects’.  
 
The model proposed by ICER in the construction of the 
imaginary DMD world is a multi-state partitioned survival 
model as it was considered to be the best fit to data available 
on DMD progression. The model was applied to a hypothetical 
cohort of patients with DMD initiating treatment at 5 years of 
age. Patients were partitioned to progress through four health 
states (early ambulatory, late ambulatory, early non-
ambulatory and later non-ambulatory) followed by death.  
Costs and QALYs were assigned to each stage with aggregate 
QALYs evaluated for the cohort as its members progressed by 
assumption through these stages. Costs and QALYs were 
discounted. 
 
The ICER model is only one of a number of alternative DMD 
imaginary worlds that have been published. Landfeldt et al 
proposed a number of cost-effectiveness model frameworks for 
DMD, all of which were lifetime models utilizing a Markov state-
transition approach30. These presented the case for a 
hypothetical intervention versus standard of care. None met 
the standards required for credible and evaluable claims. 
 
Also worth noting is the NICE assessment of the role of altaluren 
in DMD31. Although this assessment takes a UK perspective and 
resulted in an agreement for discounting and other financial 
incentives, it is of interest because of the models proposed and 
reviewed by the NIICE expert review group all of which is in the 
public domain. Again, as the models presented follow the 
requirements of the NICE reference case, the claims fail to meet 
standards for credibility and evaluation. 
 
ICER: Evidence Base  
If we accept, for the purposes of argument, a role for imaginary 
lifetime cost-per-QALY models, then a reasonable question is 
how robust must the evidence base be to go forward with 
modeling? ICER acknowledges that in modeling DMD the 
evidence base was sparse and insufficient to model specific 
treatment effects for eteplirsen and golodirsen, including in the 
latter case an analysis comparing it to corticosteroids and 
supportive care alone. In addition, the ICER report makes the 
following points in listing the key model assumptions: 
 
• There was no evidence based mechanism for relating 
treatment effects to the proportion of years spent in 
early and late ambulation or early and late non-
ambulation 
• Early and late ambulatory stages are not explicitly 
defined in the international trial data so the 
proportions by age reported in the original published 
model were applied 
• There is insufficient evidence to establish treatment 
effects on time in ambulation beyond rightward shifts 
in the survival curves. In the absence of long-term 
data, rightward shifts in the ambulation curve along 
with equivalent shifts in the mortality curve offered a 
reasonable upward bound approximation of a 
treatment effect. 
 
If there is, as ICER notes, insufficient evidence to model specific 
treatment effects, the question is why ICER continued to press 
on with its analysis and recommendations. However, as needs 
must, ICER pressed forward applying their model to see 
whether there were (as noted above), by assumption, 
‘potential’ yet imaginary treatment effects. This was achieved 
by shifting the ambulatory and mortality curves for 10, 20, 40 
years, and applying this imaginary framework to explore 
‘resulting incremental cost-effectiveness ratios given the 
eteplirsen current price’. Whether this meets any criteria of 
common sense is an open question.  To assume that current 
prices would be maintained over these timeframes appears 
odd, let alone the neglect of the potential market approval and 
entry of new therapies targeted at specific DMD gene 
mutations, together with market entry and subsequent pricing 
decisions by their manufacturers.  
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The FDA Perspective 
It is worth noting in the case of eteplirsen, where the target 
gene mutation is present in approximately 13% of the DMD 
population, the conclusions by the FDA Director for Drug 
Evaluation and Research in finding that the data submitted by 
the company met the standard for the accelerated approval of 
the drug32 . In disagreeing with a number of the findings from a 
committee review, the Director found that based on the 
surrogate endpoint of increased dystrophin protein production 
there was a reasonable likelihood of predicting clinical benefit. 
This conclusion on the surrogate endpoint, given the 
deficiencies recognized in the development program by the 
FDA ‘represents the greatest flexibility possible for FDA while 
remaining within its statutory framework’. This flexibility, the 
Director continued, ‘is warranted because: (i) the life-
threatening nature of the disease; (ii) the lack of available 
therapy; (iii) the fact that the intended population is a small 
subset of an otherwise rare disease; and (iv) the fact that this is 
a fatal disease in children’. The FDA, in allowing for the use of 
the accelerated approval pathway recognized that DMD is a 
difficult disease to study and develop treatments. It is both rare, 
presents in heterogeneous forms and lacks well established 
endpoints that span the full spectrum of the disease.  
 
ICER Model: Measuring and Valuing Health 
The ICER reference case stipulates that in measuring and 
valuing health outcomes, the instrument used for assessing 
health preferences should (i) reflect those of the general US 
population and (ii) describe those preferences usually from an 
indirect measurement based on a generic classification system.  
 
In the case of DMD, there are two groups of interest: (i) the 
DMD patient and (ii) the caregiver(s) and family. While utility 
estimates for those two groups have been proposed and 
applied in the construction of the ICER DMD construct, the issue 
as noted by Uttley et al, is whether in the case of DMD we are 
focusing on quality of life (QoL) or health related quality of life 
(HRQoL)33. The two constructs are different, although the terms 
are often used interchangeably. QoL is a multidimensional 
construct capturing physical health, personal, including 
psychological, health, beliefs, social relations and 
environmental influences. HRQoL is narrower in focusing on the 
patient’s (and caregiver(s) in pediatric and young adolescent 
populations) assessment of the impact of illness on physical, 
psychological and social interactions. In DMD, given the 
complexity of the disease stare, the broader QoL construct may 
be the more relevant measure, in its application to both 
patients and caregivers. In the case of the ICER model, the utility 
measures adopted are focused on HRQoL, not the broader QoL. 
There was apparently no choice as these QALY measures were 
the only ones available. Irrespective, therefore, of potential 
shortcomings, ICER adopted them to model their QALY claims. 
 
Even so, there is no agreement on what the broader QoL 
construct should embrace. Bann et al, in proposing a 
comprehensive model of QoL in muscular dystrophy point out 
that in their review of QoL scales none captured all of the 
domains identified in their model34. Ryder et al, in an evidence 
review of DMD noted that while the Pediatric Quality of Life 
Inventory (PedsQL) is the most frequently used tool for 
measuring HRQoL it does not correlate well with disease 
progression while a recent review of the range of muscular 
dystrophy conditions in adults point to the need for a greater 
understanding of mental wellbeing, independence and the 
management of fatigue and pain35 36. 
 
In constructing the modeled DMD imaginary world, the ICER 
options were limited to the application of utilities from a single 
paper presenting utility estimates for the stage of disease 
scored from the Health Utilities Instrument Mk 3 (HUI Mk3) for 
the hypothetical DMD patient population37. This instrument 
utilizes preferences from a Canadian population, parents with 
schoolchildren, and not a representative US population. The 
HUI Mk 3 (and its earlier Mk 2 version) includes a health status 
classification system scoring system based on standard gamble 
utilities with the scores on the conventional 0 – 1 scale. The 
scoring formula is a multiplicative multi-attribute utility 
function.  A visual analogue scoring is also available, though 
seldom used. A time-trade off technique with econometric 
modeling to generate the scoring function the scoring function  
 
The ICER report bases its estimates of caregiver burden on a 
single study by Landfeldt et al38. This analysis is designed to 
assess subjective burden associated with DMD. It utilizes a 
range of instruments supported by supplementary question to 
give an overall picture of caregiver burden. Specifically the  EQ-
5D-3L, a visual analogue scale and the SF-12 Health Survey 
supported by the Zarit Caregiver Burden Interview  together 
with supplementary caregiver questions to link patient and 
caregiver HRQoL (caregiver assessment of their son’s current 
health and mental status). ICER only utilizes the EQ-5D-3L mean 
utility scores from the Landfeldt  et al study to support the 
reference case model for its caregiver scenario analysis. 
 
If we are concerned with measuring the QoL or HRQoL  of DMD 
patients and their caregivers  then, if the HUI Mk3 is the 
centerpiece to ICER assumptions regarding patient utilities and 
the EQ-5D-3L caregiver utilities then it is appropriate to 
consider four questions 39: 
 
• Does the instrument proposed, its classification 
system, cover the attributes and the level of those 
attributes that are likely to be important to the patient 
population and caregivers under study? 
• Has the proposed instrument been used in similar 
patients and caregiver populations and was in 
response to therapy interventions and the natural 
course of the disease?  
• Is the instrument likely to be responsive to the changes 
expected in the study population and caregivers in 
constituent population groups? 
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• Does the instrument have ceiling effects or floor 
effects that will reduce its sensitivity for the patients 
and caregivers under study? 
 
While the HUI Mk3 has been used widely, the question is 
whether or not it is appropriate in capturing the range of factors 
that may impact QoL, as opposed to HRQoL in a DMD 
population. If the claim is for HRQoL than the case needs to be 
made for excluding factors that may be appropriate in QoL. 
Importantly, and this point is emphasized by Uttley et al, a 
condition specific instrument for DMD does not currently exist. 
While it is possible to identify QoL domains and sub-domains 
from DMD studies for both patients and caregivers, the key 
point is that these domains are unlikely, following Uttley et al, 
to be addressed by generic preference based instruments such 
as the HUI Mk3. Indeed, where alternative generic HRQoL 
instruments have been used the results are either inconclusive 
or contradictory.  The authors conclude: “This research 
highlights that factors relevant to QoL in DMD spans all 
domains of the included HRQoL instruments and beyond. Many 
of the nuances specific to DMD such as the impact on the carer 
and wider family, are not currently captured by standard HRQoL 
instruments. The breadth and diversity of themes and emerging 
trends in this review (e.g., impact of age within DMD) highlight 
the need to consult with patients and their families about what 
aspects of QoL need to be covered by the QoL instruments used.    
  
Although ICER, in referencing the Uttley paper, was aware of 
the criticisms of the application of generic HRQoL instruments 
to evaluating QoL in DMD patients (and the application of the 
EQ-5D-3L generic instrument in representing by assumption 
caregiver preferences) they nevertheless went ahead in 
applying the preference scores from the HUI Mk3 and the EQ-
5D in their model building. These scores are fundamental to 
their cost-per-QALY and willingness to pay threshold claims. 
Rather than ICER stepping back and allowing the development 
of a DMD instrument capturing the preferences of both 
patients, caregivers and providers the need to generate a 
report and recommendations based upon these instruments 
were, apparently, seen as paramount.  
 
Of course, if we reject the ICER modelling approach on the 
grounds that it fails to meet the standards of normal science, 
then this point becomes moot, What is important, however, is 
not the development of competing imaginary worlds, but the 
development of instruments that capture the QoL of patients, 
caregivers providers and one which can be used to evaluate the 
impact of competing therapies. 
 
Family Impact of DMD 
The impact of DMD is on the patient and the patient’s family, 
to include those family members as caregivers who are most 
involved with supporting the patient. If there is a QoL impact 
then, presumably, it should be evaluated for the family unit as 
a whole 40. It seems odd to focus on the QoL of the patient to 
the exclusion of the caregiver(s) and the caregiver(s) to the 
exclusion of the patient. The ICER modeling of HRQoL (not QoL) 
ignores this possibility and fails to offers a measure that 
combines the measurement of family QoL in assessing how 
increased survival may impact the aggregate of QoL experience 
in the family unit. To argue that the utility scores assumed 
relevant for the ICER model are the only ones available and 
should therefore be used is not acceptable.  
 
Imaginary Voting 
Following the final evidence review ICER convenes a public 
meeting with a panel to present a summary of the claims made. 
At the end of the meeting the panel is asked to vote on a series 
of questions. For DMD the ICER-convened New England 
Comparative Effectiveness Public Advisory Council (CPAC) was 
held in Boston on July 2019. The final question (of 9 asked) was 
an overview for eteplirsen “Given the available evidence on 
comparative effectiveness and incremental cost-effectiveness 
and considering other benefits, disadvantages and contextual 
considerations, what is the long term value for money of 
treatment with eteplirsen  versus supportive care and 
corticosteroids alone”.  Responses were ‘low’, ‘intermediate’ 
and ‘high’; there was no option to abstain. 
 
As argued in this commentary not only is the evidence base 
limited for DMD as a rare disease which has received 
accelerated approval, but any claims for incremental cost-
effectiveness and claims for value for money are created by a 
construct that does not meet the standards of normal science. 
The panel was asked, therefore, to vote for an imaginary world 
with no credible and evaluable claims. Whether panel members 
realized this is an open question. The result: 16 voted for ‘low’ 
imaginary value and 1 for an ‘intermediate’ imaginary value for 
the 17 panel members.  
 
Project Hercules 
The rush to judgement by ICER may be contrasted to Project 
Hercules in the UK at the School of Health and Related 
Research, University of Sheffield41. This is a multinational 
collaboration initiated in 2017 by Duchenne UK to develop tools 
and evidence to support health technology assessments and 
reimbursement decisions for new treatments in DMD.  
 
Deliverables include: 
• A critique of commonly used quality of life metrics 
(completed: see reference   ) 
• A natural history model of DMD  
• A core economic model   
• A bespoke quality of Life metric  
• A guide to health technology Assessment  
• A burden of Illness study  
 
Although not detailed by ICER in their report, Project Hercules 
is of particular interest in the recognition that there is no 
condition specific preference-based measure of DMD. They 
propose to develop the first condition specific measure for 
DMD to use in cost-effectiveness studies42. This is intended to 
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overcome deficiencies in standard generic measures, including 
the HUI Mk3 and the EQ-5D-3L that are a cornerstone of the 
ICER QALY estimates.  For example, neither the HUI Mk3 nor 
the EQ-5D adequately capture fatigue, social participation or 
dignity. The Hercules study is designed (i) to evaluate the 
content validity of these generic measures including the EQ-5D-
Y for youths and the Child Health Utility 9D while (ii) generating 
new content for either a condition specific instrument or a bolt 
on addition to an existing instrument. 
 
Stifling Innovation 
Basing recommendations for pricing of innovative products, 
particularly those targeting rare disease populations, on the 
constructed evidence of an imaginary world must raise 
concerns about the impact of ICER’s hypothetical claims on the 
willingness to invest in these products. Unlike the FDA who in 
the case of eteplirsen granted accelerated approval status 
based on a surrogate endpoint following an exhaustive 
evidence review, the ICER recommendations are based on 
constructed evidence. As emphasized above, constructing 
evidence to support pricing recommendations is, from the 
standpoint of the methods of normal science, unacceptable. A 
show of hands to vote on whether or not the ICER constructed 
modeled evidence demonstrates cost-effectiveness is hardly 
satisfactory.  
 
ICER notes in the preamble to the DMD report that ‘Readers 
should be aware that new evidence may emerge following the 
publication of this report that could potentially influence the 
results. ICER may (emphasis added) revise its analysis in a 
formal update to this report in the future’. While this is laudable 
it is unnecessary, the fact remains that in its rush to judgement 
ICER has not only produced recommendations from a 
constructed imaginary world while also recognizing that the 
evidence base is sparse. Promising further DMD imaginary 
world iterations is hardly reassuring. A more appropriate 
approach might have been to follow the initiative of Project 
Hercules and support the establishment of a more 
comprehensive evidence base to support credible and 
evaluable claims.  
 
Conclusions 
As detailed in this commentary and in previous commentaries 
on ICER’s reference case methodology, the approach taken by 
ICER in constructing imaginary worlds to support pricing 
recommendations fails to meet the standards of normal 
science. The approach should be seen as pseudoscience and 
any conclusions reached subject to this caveat. 
 
If we accept the position taken by the CADTH guidelines that 
the role of model building in health technology assessment is to 
inform decisions, a reasonable question is how a health system 
decision maker is to value the information provided. How is the 
decision maker to judge the weight to be given to a non-
evaluable cost-per-QALY claim? How does the decision maker 
judge the ‘take our word for it’ approach of ICER if there are 
concerns regarding differing frameworks and outcome 
scenarios offered by competing models?  
 
To argue that the role of hypothetical lifetime models is to 
provide information to formulary committees and others is 
beside the point. Any model can be challenged on it structure 
and its supporting assumptions. Even, if as seems likely, the 
proposed Project Hercules preference based measure 
calibrated for measuring HRQoL (QoL?) in DMD patients and 
caregivers is judged adequate, this does not mean that its 
presence justifies its application in reference case models. The 
model, unless the claims are credible and evaluable, would still 
fail to meet the standards of normal science. The same 
argument would apply to ‘improved’ direct medical cost 
measures even if they include costs borne by caregivers and the 
family. It seems appropriate to abandon the phrase ‘for 
information’ in favor of ‘knowledge’, accepting a framework in 
health technology assessment that focuses on technology 
adoption and credible, evaluable and replicable knowledge 
accumulation. 
 
This ICER position is made that more questionable by the 
likelihood that no one on a formulary committee has any skills 
in model building; the ICER model is  a ‘black box’.  It would be 
probably unwise to fall back on the ICER ‘voting’ procedures as 
those voting, as noted, are probably also unfamiliar with model 
building. As it stands, health care decision makers have a 
number of DMD models to choose from in addition to the ICER 
model, particularly with reference to competing estimates of 
QALYs. Additional models are in production, notably model(s) 
associated with the DMD Project Hercules. All would be 
rejected if they were focused on reference case scenarios. 
 
Constructing imaginary worlds to justify product pricing and 
access decisions should be seen as an analytical dead end. As 
noted, we have no idea whether the claims and their supporting 
models are ‘right’ or if they are ‘wrong’ both in their structure, 
assumptions and conclusions, and we will never know. Indeed, 
with a hypothetical cohort, in this case of 5-year old DMD 
patients tracked by assumption over the next 10, 20 or 30 years 
we were never intended to make a judgement. All ICER offers 
are recommendations based on the ratio of assumed lifetime 
QALYs to assumed lifetime costs. 
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